Physician profile
Faiza Ali
NPI 1891137360
$9,234.17
in general payments reported to CMS, 2019-2025
42 companies · $1,118 in 2025
The $1,118 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,038 · 2020: $1,070 · 2021: $1,896 · 2022: $1,483 · 2023: $1,409 · 2024: $1,219 · 2025: $1,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,648 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,647.65 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,418.67 | 2019-2025 | |
| Novo Nordisk INC | $1,285.82 | 2019-2025 | Ozempic |
| Abbvie INC. | $1,077.04 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,034.34 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $979.23 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Abbott Laboratories | $469.42 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Daiichi Sankyo INC. | $255.05 | 2020-2023 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.38 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Exact Sciences Corporation | $253.54 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $238.21 | 2019-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $215.14 | 2021-2025 | Veozah |
| Allergan, INC. | $193.22 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $157.81 | 2019-2023 | Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $144.06 | 2022-2024 | Shingrix |
| Sanofi-Aventis U.S. LLC | $117.41 | 2022-2024 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faiza Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.